US provider of virtual product development (VPD) technologies
MSC.Software has come up with a range of new software and services
packages targeted at the biomedical market and medical device
Danish Novo Nordisk plans to break ground on a €10 million
expansion of its insulin manufacturing facility in Clayton, US. The
company has awarded the contract to BE&K Engineering and Suitt
Construction for the 19,000-square-foot...
Outsourcing drug discovery functions is a rapidly growing trend
that has led to a nearly $2 billion (€1.7bn) industry worldwide,
according to a new study released this week by Kalorama
Information, and contract services in the field...
Balchem reported a small rise in net sales, up 3 per cent overall
during the first quarter of 2003, but said it was pleased with
results in light of the continued difficult economic environment.
Net earnings at the New York-based...
Paris, France-based speciality chemicals company Rhodia has
reported a disappointing set of first quarter figures that reflects
what the firm describes as "a difficult economic and geopolitical
environment" and "a trough...
Danish biotech company Fluxome Sciences , based at the Technical
University of Denmark, has entered a cooperation agreement with the
US biotech company Bio-Technical Resources concerning development
of optimised fermentation processes,...
Strasbourg, France-based Aventis has announced its intention to
sell off part of its remaining stake in Rhodia, its loss-making
former specialty chemicals subsidiary. The move reduces its stake
in Rhodia to 15.3 per cent from 25.2...
As consolidation continues to mark the pharmaceutical industry,
more evidence to suggest that companies will increasingly turn to
biotechnology companies in order to gain the competitive edge comes
from a new study from Cutting Edge...
US company PPD is taking a stake in Chemokine Therapeutics, a
Canadian- and US-based biotechnology company, to continue
development of a proprietary peptide derived from a particular
chemokine that may make the peptide useful as a...
US provider of drug discovery tools Deltagen saw cutbacks in
workforce and the closure of operating units help boost revenue by
93 per cent for the fourth quarter of 2002 to $4.7 million (€4.3m),
compared to $2.5 million (€2.3m) for...
Total revenues for the four emerging sectors of protein array,
crucial antibody array, peptide biochip, protein biochip, and
solution bead/particle array were estimated at $90 million
(€83million) in 2002, writes market analyst Business...
Millipore, which specialises in providing technologies, tools and
services for the discovery, development and production of new
therapeutic drugs, has reported first-quarter 2003 sales of $187
million (€173 million), up 13 per cent...